Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

Published:2017-02-07 Issue:2 Volume:177 Page:254-262
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Berdeja Jesus G.¹²,Bauer Todd¹²,Arrowsmith Edward¹³,Essell James¹⁴,Murphy Patrick¹²,Reeves James A.¹⁵,Boccia Ralph V.⁶,Donnellan William¹²,Flinn Ian¹²

Affiliation:

1. Sarah Cannon Research Institute; Nashville TN USA

2. Tennessee Oncology PLLC; Nashville TN USA

3. Tennessee Oncology PLLC; Chattanooga TN USA

4. Oncology Hematology Care, Inc; Cincinnati OH USA

5. Florida Cancer Specialists; Ft. Myers FL USA

6. Center for Cancer and Blood Disorders; Bethesda MD USA

Funder

Takeda Pharmaceutical Company

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14536/fullpdf

Reference23 articles.

1. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;Benboubker;New England Journal of Medicine,2014

2. IMWG consensus on risk stratification in multiple myeloma;Chng;Leukemia,2014

3. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

4. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma;Fenk;Leukemia and Lymphoma,2007

5. Combination therapy of bortezomib with bendamustine in elderly patients with advanced multiple myeloma. Clinical observation;Hrusovsky;Blood,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function;2023-12-11

2. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

3. Current and Novel Alkylators in Multiple Myeloma;Cancers;2021-05-18

4. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV);Journal of Cancer Research and Clinical Oncology;2021-01-12

5. Emerging agents and regimens for multiple myeloma;Journal of Hematology & Oncology;2020-11-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3